At least nine biotechs and pharmas reported earnings last week. Actelion Ltd. (SIX:ATLN) added almost $300 million in market value after raising its 2012 core earnings guidance to mid-single digit growth from no growth. The company said the revision was "based on an accelerated impact from the cost saving initiative" announced earlier this month. Actelion said it continues to expect product sales to decrease in the low single-digit range due to price cuts in some markets and increased competition in the U.S. for pulmonary arterial hypertension (PAH) drugs Tracleer bosentan and Ventavis iloprost. Molecular diagnostic company Cepheid Inc. (NASDAQ:CPHD) fell 15% on the week after lowering its non-GAAP EPS guidance to $0.38-$0.42 from $0.50-$0.55 because of anticipated pricing discounts under its program to bring in vitro diagnostics to high need countries. (A) Fiscal 1Q13 earnings; Mcap in $M


2Q12 EPS est

2Q12 EPS actual


Growth from 2Q11

7/20 cls

Wk chg

% chg

Mcap chg

7/20 Mcap

Abbott Laboratories (NYSE:ABT)



Beat by $0.01







2Q12 total sales increased 7% to $9.8B from $9.6B in 2Q11. Sales of proprietary pharmaceuticals increased 9% to $4.4B. Global sales of autoimmune drug Humira adalimumab increased 23% to $2.3B. Percent changes are in constant currency. Abbott reiterated it is on track to separate into two companies - a diversified medical products company and a research-based pharmaceutical company - by year end. The company continues to expect FY12 EPS of $5-$5.10.